Trials / Not Yet Recruiting
Not Yet RecruitingNCT07515950
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 244 (estimated)
- Sponsor
- MedSIR · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The REVEAL-BTC Study will analyze 5 biomarkes in samples of participants who in the past 15 year have been diagnosed with any stage of biliary tract cancer. The expression levels of the biomarkers will be correlated with clinical outcomes in the participants, which will lead to better patient stratification that will help guide the use of targeted therapies in the future.
Detailed description
In the REVEAL.BCT Study, archival tumor tissue samples available from multiple national sites in Spain will be collected alongside basic clinical and survival data of 244 participants. Then, samples will be evaluated for the expression of selected biomarkers (CLDN18.2, TROP2, B7-H4, HER2, and PD-L1) via immunohistochemistry. The main purpose of this analysis is to evaluate the expression levels of the biomarkers and understand its link to the participants' clinical outcome, with the aim to identify specific patient populations and strategies to help clinicians guide the use of targeted therapies in patients according to their markers in the future.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Non applicable |
Timeline
- Start date
- 2026-07-01
- Primary completion
- 2027-05-01
- Completion
- 2027-07-01
- First posted
- 2026-04-07
- Last updated
- 2026-04-07
Source: ClinicalTrials.gov record NCT07515950. Inclusion in this directory is not an endorsement.